John K. Pratt

Publications by Year

Research Areas

Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, CAR-T cell therapy research, HIV/AIDS drug development and treatment, Ubiquitin and proteasome pathways

Most-Cited Works

• → Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer(2020)393 cited
• → Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor(2017)134 cited
• → Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A(2014)126 cited
• → Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro(2005)120 cited
• → Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies(2017)118 cited
• → Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain(2020)117 cited
• → Nonsteroidal Selective Glucocorticoid Modulators: the Effect of C-5 Alkyl Substitution on the Transcriptional Activation/Repression Profile of 2,5-Dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines(2001)111 cited
• → Nonsteroidal Selective Glucocorticoid Modulators: The Effect of C-10 Substitution on Receptor Selectivity and Functional Potency of 5-Allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines(2003)107 cited
• → A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans(2003)86 cited
• → Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors(2017)64 cited